A sandostatin analog, TT-232 (D-Phe-c[Cys-Tyr-D-Trp-Lys-Cys]-Thr-NH2), exhibits strong antitumor effects both in vitro and in vivo. In order to study the structure-activity relationships of TT-232, we designed and synthesized an analog of TT-232, namely Lan-7, in which the disulfide bridge is replaced by a lanthionine monosulfide bridge. Conformational analysis by NMR spectroscopy and computer simulations revealed that Lan-7 and TT-232 adopt very similar conformations in solution, which are quite different from the preferred conformations of sandostatin. Lan-7 has significant growth inhibition effects on a number of human tumor cell lines. It can also induce apoptosis in human ovarian carcinoma 2008 cells. At the same time, Lan-7 produced no toxicity to normal human hematopoietic progenitor cells. All of these results indicate that the modification we made does not alter the anti-tumor activity of TT-232. Copyright (C) 2000 European Peptide Society and John Wiley and Sons, Ltd.
CITATION STYLE
Li, H., Jiang, X., Howell, S. B., & Goodman, M. (2000). Synthesis, conformational analysis and bioactivity of Lan-7, a lanthionine analog of TT-232. Journal of Peptide Science, 6(1), 26–35. https://doi.org/10.1002/(SICI)1099-1387(200001)6:1<26::AID-PSC231>3.0.CO;2-6
Mendeley helps you to discover research relevant for your work.